In a separate editorial, also published in the January issue of Cancer Prevention Research, Charles M. Rudin, M.D., Ph.D., wrote that "this new study of cyclooxygenase inhibition, together with recent data on the efficacy of the hedgehog pathway inhibition, offer new hope for patients at a high risk for basal cell cancer."
"Basal cell carcinoma is an incredibly common disease, far and away the most common cancer in people. The potential for a therapy that would impact the incidence of this would be huge," said Rudin, associate director for clinical research at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins.
Rudin told the American Association for Cancer Research that while the clinical results of this study do not have an immediate impact for patients with basal cell carcinoma, Epstein and colleagues have set a precedent for future clinical trials.
So how do these findings translate to the clinic?
In another accompanying editorial, also published in the same issue of Cancer Prevention Research, Jack L. Arbiser, M.D., Ph.D., wrote that these results demonstrate a pivotal role in the pathogenesis of basal cell carcinoma and point towards combination therapy among those with this form of cancer.
"This has implications for public health," said Arbiser, professor of dermatology in the Department of Dermatology at Emory University School of Medicine.
Although the results of this study showed positive results in reducing cancer, Epstein suggested that concerns remain about the potential cardiovascular side effects (i.e., stroke or heart attack) that may be associated with this drug. More studies are needed to validate the safety and efficacy of the use of celecoxib in this population.
|Contact: Tara Yates|
American Association for Cancer Research